Oracle Called $20B Its Final Raise, Then Raised It All in Five Days

At its October 28 investor day, Oracle drew a line for investors. CFO Hilary Maxson said the final outside funding needed to finish this investment cycle was $20 billion. Half would be equity, half debt.

The stock closed up 10.7% that day at $144.54. Five days later, on the evening of November 2, Oracle raised that $20 billion in one go. The shares fell 8.8% the same day to $119.22.

Oracle Used Up Its Cap in Five Days

According to the company's release, Oracle sold 86.2 million new shares at $116. That price is 11.2% below the October 30 close. Alongside it came $10 billion of bonds in five tranches maturing between 2029 and 2046.

Coupons run from 7% to 8.65%. The annual interest bill on the new debt is about $777 million. Expected ratings are Baa2 with a negative outlook at Moody's and BBB- at S&P, the lowest investment-grade rung.

In February Oracle sold $25 billion of bonds and $5 billion of mandatory convertible preferred stock, then sold $20 billion of shares piecemeal over the summer. This time it did not exceed the cap; it used all of it in five days.

Why the Same Money Cost More

On October 28 the market priced the cap itself. On November 2 it priced the terms on which the cap was filled. The difference shows up in two places: the number of shares issued and the interest paid.

The same mechanism is at work on the debt side. According to secondary reports, the 2046 tranche priced 335 basis points over Treasuries. A similar maturity in February priced at 170 basis points.

The yield on the 2046 tranche rose from 6.56% to 8.67%. On that single $1.5 billion tranche, the gap is about $32 million a year, or $633 million over twenty years. For how yields and bond prices relate, see Rates and Bonds.

Oracle's share price over the past three months places the investor day and the funding announcement in one frame:

The Side That Shows Demand Was There

There is another side to the story. According to reports, initial price talk on the longest tranche was about 360 basis points over Treasuries. Strong demand tightened the final spread by 25 basis points.

The prospectus bars Oracle from selling new shares for 60 days without the lead underwriter's consent. Maxson had also called the amount the final funding of the cycle. The company kept its word; it simply took the money earlier, and at a lower price, than expected.

The cash picture did not change. Oracle ended fiscal 2026 with negative free cash flow of $23.7 billion and carries $125.3 billion of debt. It expects free cash flow to turn positive in the second half of fiscal 2028; for background see Cash Flow.

What It Means for Investors

• The market had priced the existence of new funding on October 28; on November 2 it priced an 11.2% discount and a borrowing cost close to double February's.
• The spread Oracle paid becomes a benchmark for debt-funded AI builders such as CoreWeave and for Meta, which is preparing a bond sale.
• The threshold to watch is the 60-day sale restriction: any new stock or bond sale before it ends would undercut the "final amount" pledge.
• The risk that would sharpen this reading is Moody's turning its negative outlook into a downgrade, which would put Oracle on the lowest investment-grade rung.

For comparison, the fund tracking the Nasdaq 100 over the same period is shown below:

Oracle's loss came within a broad tech selloff, but its cause was the company's own funding terms.

Colophon: Share and bond terms come from Oracle's November 2 release. Investor day statements rely on the company's October 28 presentation and 24/7 Wall St.'s report. Bond spreads and the February comparison come from secondary reports; the company did not disclose them separately. Closing prices were cross-checked with market notes from TradingKey and Saxo.